NCT05369065View on ClinicalTrials.gov

Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2029

Conditions
Diabetes Mellitus, Type 2Hypertension
Interventions
COMBINATION_PRODUCT

Ablation Treatment

Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter

DIAGNOSTIC_TEST

Arterial Angiography Only

Arterial Angiography Only without Intervention

COMBINATION_PRODUCT

Single Arm non-Randomized Ablation Treatment

Denervation of renal and common hepatic arteries by ethanol ablation with the Neurotronic Infusion Catheter

Trial Locations (3)

0112

RECRUITING

Israeli-Georgian Medical Research Clinic Helsicore, Tbilisi

0159

RECRUITING

Tbilisi Heart and Vascular Clinic, Tbilisi

0186

RECRUITING

Tbilisi Heart Center, Tbilisi

Sponsors

Lead Sponsor

Neurotronic, Inc.

Collaborators (1)

Libra Medical
All Listed Sponsors
collaborator

Libra Medical

OTHER

lead

Neurotronic, Inc.

INDUSTRY